Search research articles
Contact Us
Filters
Showing results (151-160 of 323) with videos related to
Page
of 33
Sort By:
The Oncologist
|
July 7, 2016
Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer
Roberto Moretto, Chiara Cremolini, Daniele Rossini, et al.
British Journal of Cancer
|
February 9, 2023
Trop-2 and Nectin-4 immunohistochemical expression in metastatic colorectal cancer: searching for the right population for drugs' development
Roberto Moretto, Marco Maria Germani, Mirella Giordano, et al.
Clinical Drug Investigation
|
June 17, 2024
Radiomic Parameters for the Evaluation of Response to Treatment in Metastatic Colorectal Cancer Patients with Liver Metastasis: Findings from the CAVE-GOIM mCRC Phase 2 Trial
Erika Martinelli, Davide Ciardiello, Giulia Martini, et al.
Acta Oncologica (Stockholm, Sweden)
|
April 22, 2024
Gender Difference in sidE eFfects of ImmuNotherapy: a possible clue to optimize cancEr tReatment (G-DEFINER): study protocol of an observational prospective multicenter study
Rosalba Miceli, Hanna Eriksson, Giuseppe Lo Russo, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 13, 2023
Optimal maintenance strategy following FOLFOX plus anti-EGFR induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of randomised clinical trials
Alessandra Raimondi, Federico Nichetti, Arndt Stahler, et al.
JCO Precision Oncology
|
October 5, 2023
Predictive Impact of <i>RNF43</i> Mutations in Patients With Proficient Mismatch Repair/Microsatellite Stable <i>BRAFV600E</i>-Mutated Metastatic Colorectal Cancer Treated With Target Therapy or Chemotherapy
Roberto Moretto, Marco Maria Germani, Javier Ros, et al.
JCO Precision Oncology
|
November 7, 2024
KRASG12D-Mutated Metastatic Colorectal Cancer: Clinical, Molecular, Immunologic, and Prognostic Features of a New Emerging Targeted Alteration
Roberto Moretto, Daniele Rossini, Sabina Murgioni, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 14, 2021
Exploring clinical and gene expression markers of benefit from FOLFOXIRI/bevacizumab in patients with BRAF-mutated metastatic colorectal cancer: Subgroup analyses of the TRIBE2 study
Roberto Moretto, Mirella Giordano, Anello M Poma, et al.
Oncology
|
September 8, 2017
Preoperative Capecitabine, Oxaliplatin, and Irinotecan in Resectable Gastric or Gastroesophageal Junction Cancer: Pathological Response as Primary Endpoint and FDG-PET Predictions
Rosa Berenato, Federica Morano, Filippo Pietrantonio, et al.
Cancer Research
|
July 10, 2025
AREG and EREG Are Predictive Biomarkers of Response to EGFR Inhibition in Gastroesophageal Cancer
Daniela Conticelli, Marco Volante, Filippo Pietrantonio, et al.
Page
of 33
Search research articles
Search
Showing results (151-160 of 323) with videos related to
Sort By:
Page
of 33
The Oncologist
|
July 7, 2016
Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer
Roberto Moretto, Chiara Cremolini, Daniele Rossini, et al.
British Journal of Cancer
|
February 9, 2023
Trop-2 and Nectin-4 immunohistochemical expression in metastatic colorectal cancer: searching for the right population for drugs' development
Roberto Moretto, Marco Maria Germani, Mirella Giordano, et al.
Clinical Drug Investigation
|
June 17, 2024
Radiomic Parameters for the Evaluation of Response to Treatment in Metastatic Colorectal Cancer Patients with Liver Metastasis: Findings from the CAVE-GOIM mCRC Phase 2 Trial
Erika Martinelli, Davide Ciardiello, Giulia Martini, et al.
Acta Oncologica (Stockholm, Sweden)
|
April 22, 2024
Gender Difference in sidE eFfects of ImmuNotherapy: a possible clue to optimize cancEr tReatment (G-DEFINER): study protocol of an observational prospective multicenter study
Rosalba Miceli, Hanna Eriksson, Giuseppe Lo Russo, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 13, 2023
Optimal maintenance strategy following FOLFOX plus anti-EGFR induction therapy in patients with RAS wild type metastatic colorectal cancer: An individual patient data pooled analysis of randomised clinical trials
Alessandra Raimondi, Federico Nichetti, Arndt Stahler, et al.
JCO Precision Oncology
|
October 5, 2023
Predictive Impact of <i>RNF43</i> Mutations in Patients With Proficient Mismatch Repair/Microsatellite Stable <i>BRAFV600E</i>-Mutated Metastatic Colorectal Cancer Treated With Target Therapy or Chemotherapy
Roberto Moretto, Marco Maria Germani, Javier Ros, et al.
JCO Precision Oncology
|
November 7, 2024
KRASG12D-Mutated Metastatic Colorectal Cancer: Clinical, Molecular, Immunologic, and Prognostic Features of a New Emerging Targeted Alteration
Roberto Moretto, Daniele Rossini, Sabina Murgioni, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 14, 2021
Exploring clinical and gene expression markers of benefit from FOLFOXIRI/bevacizumab in patients with BRAF-mutated metastatic colorectal cancer: Subgroup analyses of the TRIBE2 study
Roberto Moretto, Mirella Giordano, Anello M Poma, et al.
Oncology
|
September 8, 2017
Preoperative Capecitabine, Oxaliplatin, and Irinotecan in Resectable Gastric or Gastroesophageal Junction Cancer: Pathological Response as Primary Endpoint and FDG-PET Predictions
Rosa Berenato, Federica Morano, Filippo Pietrantonio, et al.
Cancer Research
|
July 10, 2025
AREG and EREG Are Predictive Biomarkers of Response to EGFR Inhibition in Gastroesophageal Cancer
Daniela Conticelli, Marco Volante, Filippo Pietrantonio, et al.
Page
of 33